Half Of 1st Approved Generics Do Not Launch Due To Part D Formulary Obstacles, AAM Says
Executive Summary
Medicare Part D program should place generics on tiers separate from brand drugs and create a dedicated tier for specialty generics and biosimilars, AAM advocates in white paper.
You may also be interested in...
US Substitution Rates Lower For Higher Cost Brands
Study sponsored by Association for Accessible Medicines suggests quirks in Part D benefit design and rebating practices are driving the trend.
Medicare Part D Generic Substitution Rates Lower For Higher Cost Brands
Study sponsored by Association for Accessible Medicines suggests quirks in Part D benefit design and rebating practices are driving the trend.
PhRMA Continues Push For Medicare Part D Redesign In Drug Pricing Legislation
PhRMA exec discusses industry's opposition to generic mandates in formularies, its continued hope for rebate reform, and the damage Pelosi's bill could spawn even if it fails.